All In Biotech

Investigational drug · Phase 2

Cadefrecitinib

Also called: GLPG3667

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatomyositis, Systemic Lupus Erythematosus.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

0 still active

All registered trials

2

Any phase or sponsor naming "Cadefrecitinib"

First trial start

2023

Feb 27, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cadefrecitinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Dermatomyositis
  • Systemic Lupus Erythematosus

Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "Cadefrecitinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Dermatomyositis

  • NM8074Phase 28 trials

    NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria

  • PN-101Phase 21 trial

    Paean Biotechnology Inc. · Polymyositis, Dermatomyositis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.